QLT PhotoTherapeutics (QLTI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Ian@SI who wrote (842)	3/15/2000 5:14:00 PM
From: Ian@SI	Read Replies (1) of 1321

I decided that my response to a PM was probably of general interest to the thread. It was: +++++++++++ Stew, The amount of Visudyne that will be sold is a function of the number of sites that have the facilities (e.g. Lasers) and the trained staff to administer the exams, injections and laser exposure. There were 200 sites. There will be an additional 200 sites. Once approval is received, twice as many Visudyne doses can be sold daily as would have been the case otherwise. Essentially, we can expect QLT to meet or beat current revenue projections even with the FDA delay. This is not testing, this is training additional Visudyne delivery professionals - an FDA requirement before it can be sold. IMO, this is a positive announcement. Neither company would make the incremental investment if they weren't quite confident of an imminent payoff. Ian. ++++++++The query was: +++++++++++++++ Hello Ian: Is a month enough time for the extra sites to produce and submit results? I was wondering if the right way to read that NR is "Oops! We didn't get FDA approval but we can expand our testing." But then . . . I probably haven't been in as long as you have. Would be interested in your further thoughts on this. Tks.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next